^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Neuroblastoma

    Related cancers:
    Apply
    NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma (NCT07211737)
    Phase 1
    Baylor College of Medicine
    Not yet recruiting
    Last update posted :
    10/08/2025
    Initiation :
    11/01/2025
    Primary completion :
    12/01/2028
    Completion :
    12/01/2043
    NKG2D
    A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma (NCT07085338)
    Phase 2
    St. Jude Children's Research Hospital
    Not yet recruiting
    Last update posted :
    07/25/2025
    Initiation :
    07/01/2025
    Primary completion :
    02/01/2028
    Completion :
    02/01/2029
    CSF2
    |
    temozolomide • irinotecan • Anktiva (nogapendekin alfa inbakicept-pmln) • daretabart (hu1418K322A) • Leukine (sargramostim)
    NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors (NCT01875601)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    06/11/2013
    Primary completion :
    09/08/2015
    Completion :
    09/08/2015
    CD4
    |
    cyclophosphamide • rhIL-15
    Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (NCT04901702)
    Phase 1/2
    St. Jude Children's Research Hospital
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/09/2021
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    EWSR1 • FLI1
    |
    temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)
    A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma (NCT04936529)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    08/02/2021
    Primary completion :
    06/15/2025
    Completion :
    06/15/2025
    MYC • MYCN • CSF2
    |
    MYCN amplification
    Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (NCT06172296)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    04/19/2024
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    ALK • TERT • MYCN
    |
    cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane
    Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors (NCT05429502)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    12/27/2022
    Primary completion :
    10/15/2027
    Completion :
    01/28/2028
    MYCN • SMARCB1
    |
    IDH wild-type
    |
    temozolomide • Kisqali (ribociclib) • topotecan
    Neuroblastoma Precision Trial (NCT02868268)
    Phase N/A
    New Approaches to Neuroblastoma Therapy Consortium
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    08/22/2016
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    PD-L1 • ALK
    MCT for the Harvard/UCSF ROBIN Center (NCT06000787)
    Phase N/A
    Brigham and Women's Hospital
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    09/19/2023
    Primary completion :
    08/31/2028
    Completion :
    08/31/2028
    MYCN
    |
    MYCN amplification
    |
    Azedra (iobenguane I 131)
    Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (NCT03794349)
    Phase 2
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/08/2019
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    IFNG • IL6 • CD276 • TNFA
    |
    temozolomide • irinotecan • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (NCT03126916)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    05/14/2018
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    MYCN
    |
    MYCN amplification
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • busulfan • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane • Leukine (sargramostim)
    Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma (NCT02909777)
    Phase 1
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    10/01/2016
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    MYC • MYCN
    |
    MYCN expression
    |
    fimepinostat (CUDC-907)